- Home
- GNSS vs BCAB Comparison
GNSS vs BCAB Comparison
Compare GNSS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- BCAB
- Stock Information
- Founded
- GNSS 1992
- BCAB 2007
- Country
- GNSS United States
- BCAB United States
- Employees
- GNSS N/A
- BCAB N/A
- Industry
- GNSS Consumer Electronics/Appliances
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- GNSS Consumer Staples
- BCAB Health Care
- Exchange
- GNSS Nasdaq
- BCAB Nasdaq
- Market Cap
- GNSS 169.5M
- BCAB 96.2M
- IPO Year
- GNSS N/A
- BCAB 2020
- Fundamental
- Price
- GNSS $3.75
- BCAB $2.08
- Analyst Decision
- GNSS Strong Buy
- BCAB Strong Buy
- Analyst Count
- GNSS 3
- BCAB 2
- Target Price
- GNSS $5.08
- BCAB $6.00
- AVG Volume (30 Days)
- GNSS 106.7K
- BCAB 1.6M
- Earning Date
- GNSS 12-05-2024
- BCAB 11-08-2024
- Dividend Yield
- GNSS N/A
- BCAB N/A
- EPS Growth
- GNSS N/A
- BCAB N/A
- EPS
- GNSS N/A
- BCAB N/A
- Revenue
- GNSS $27,968,000.00
- BCAB N/A
- Revenue This Year
- GNSS N/A
- BCAB N/A
- Revenue Next Year
- GNSS $138.10
- BCAB N/A
- P/E Ratio
- GNSS N/A
- BCAB N/A
- Revenue Growth
- GNSS N/A
- BCAB N/A
- 52 Week Low
- GNSS $1.51
- BCAB $1.14
- 52 Week High
- GNSS $4.04
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- GNSS 60.29
- BCAB 55.80
- Support Level
- GNSS $3.67
- BCAB $1.87
- Resistance Level
- GNSS $3.94
- BCAB $2.13
- Average True Range (ATR)
- GNSS 0.14
- BCAB 0.12
- MACD
- GNSS -0.02
- BCAB 0.00
- Stochastic Oscillator
- GNSS 77.78
- BCAB 68.90
About GNSS Genasys Inc.
Genasys Inc is a provider of critical communications solutions designed to help keep people safe. The company is engaged in the design, development, and commercialization of directed and multidirectional sound technologies, voice broadcast products and location-based mass messaging solutions for emergency warning and workforce management. Its operating segment includes Hardware and Software. The company generates maximum revenue from the Hardware segment. Geographically, it derives a majority of revenue from the Americas region and also has its presence in the Asia Pacific and Europe, Middle East and Africa.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.